跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SKYRIZI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SKYRIZI
Authorized
STANDARD
SKYRIZI
Abbvie Corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
36cc5324b2eee0fd
Company
Abbvie Corporation
Type
Standard
Approval Details
Approval Id
36cc5324b2eee0fd
Drug Approval Canada Name
SKYRIZI
Product Name
SKYRIZI
Status
Marketed
Status Date
2023-03-14
Original Market Date
2023-03-14
Din
02532093
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
84:06.28
Atc Original
L04AC18 RIZANKIZUMAB
Atc Name
l 04 ac 18
Aig Number
0161390002
Company Name
Abbvie Corporation
Company Address
8401 Trans-Canada Highway, Saint-Laurent, Quebec, Canada, H4S 1Z1
Company Detail Path
/organization/abbvie-corporation
Company Information
Pharmaceutical Company Name
Abbvie Corporation
Country Name
Canada
Province Name
Quebec
City Name
saint-laurent,quebec,country_ca
Address
8401 rte Transcanadienne
Active Ingredients
RISANKIZUMAB
360 MG / 2.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
36cc5324b2eee0fd
Type
Standard
Back to Health Canada Approvals